By Biogen | December 21, 2017Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18 Month Endpoint
By Biogen | November 28, 2017Biogen & Alkermes Strike Commercialization & Development Deal for MS Treatment
